TW202341988A - Ｉｋｚｆ２降解劑及其用途 - Google Patents
Ｉｋｚｆ２降解劑及其用途 Download PDFInfo
- Publication number
- TW202341988A TW202341988A TW112111194A TW112111194A TW202341988A TW 202341988 A TW202341988 A TW 202341988A TW 112111194 A TW112111194 A TW 112111194A TW 112111194 A TW112111194 A TW 112111194A TW 202341988 A TW202341988 A TW 202341988A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- carbocyclyl
- compound
- alkyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323792P | 2022-03-25 | 2022-03-25 | |
| US63/323,792 | 2022-03-25 | ||
| US202363446105P | 2023-02-16 | 2023-02-16 | |
| US63/446,105 | 2023-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202341988A true TW202341988A (zh) | 2023-11-01 |
Family
ID=86185384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112111194A TW202341988A (zh) | 2022-03-25 | 2023-03-24 | Ｉｋｚｆ２降解劑及其用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250215012A1 (enExample) |
| EP (1) | EP4499649A1 (enExample) |
| JP (1) | JP2025512805A (enExample) |
| KR (1) | KR20250026153A (enExample) |
| CN (1) | CN119731179A (enExample) |
| TW (1) | TW202341988A (enExample) |
| WO (1) | WO2023183540A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| EP4471033A4 (en) * | 2022-01-29 | 2026-03-25 | Gan & Lee Pharmaceuticals Co Ltd | CEREBLON UBIQUITIN LIGASE E3 INHIBITOR |
| CN117065022A (zh) * | 2022-05-17 | 2023-11-17 | 海创药业股份有限公司 | 一种治疗三阴乳腺癌的药物 |
| WO2025261456A1 (zh) * | 2024-06-19 | 2025-12-26 | 甘李药业股份有限公司 | 一种雌激素受体蛋白降解靶向嵌合体化合物及其应用 |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
| WO2026139085A1 (zh) * | 2024-12-27 | 2026-07-02 | 甘李药业股份有限公司 | 酪蛋白激酶1α(CK1α)分子胶降解剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CA3123519A1 (en) * | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021087093A1 (en) * | 2019-10-30 | 2021-05-06 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| EP4168007A1 (en) * | 2020-06-23 | 2023-04-26 | Novartis AG | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4188549A1 (en) * | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
-
2023
- 2023-03-24 TW TW112111194A patent/TW202341988A/zh unknown
- 2023-03-24 US US18/849,594 patent/US20250215012A1/en active Pending
- 2023-03-24 EP EP23719521.9A patent/EP4499649A1/en active Pending
- 2023-03-24 WO PCT/US2023/016177 patent/WO2023183540A1/en not_active Ceased
- 2023-03-24 JP JP2024556604A patent/JP2025512805A/ja active Pending
- 2023-03-24 CN CN202380041783.5A patent/CN119731179A/zh active Pending
- 2023-03-24 KR KR1020247035795A patent/KR20250026153A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250026153A (ko) | 2025-02-25 |
| US20250215012A1 (en) | 2025-07-03 |
| JP2025512805A (ja) | 2025-04-22 |
| EP4499649A1 (en) | 2025-02-05 |
| WO2023183540A1 (en) | 2023-09-28 |
| CN119731179A (zh) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112166110B (zh) | Shp2磷酸酶抑制剂及其使用方法 | |
| TWI664175B (zh) | 用於作為shp2抑制劑之新穎雜環衍生物 | |
| KR20250135228A (ko) | Vav1의 표적 분해 | |
| KR101862493B1 (ko) | Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체 | |
| JP5824055B2 (ja) | Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤 | |
| KR101701663B1 (ko) | 3-치환된 피라졸 및 dlk 억제제로서의 용도 | |
| TW202446371A (zh) | ２－氮雜雙環［２．２．１］庚烷ｋｒａｓ抑制劑 | |
| JP2024527570A (ja) | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 | |
| KR20250026153A (ko) | Ikzf2 분해제 및 이의 용도 | |
| KR20220061958A (ko) | Cd38의 억제제로서의 헤테로바이사이클릭 아미드 | |
| KR20210075110A (ko) | 질소 함유 헤테로방향족 유도체의 조절제, 이의 제조 방법 및 이의 용도 | |
| JP7549597B2 (ja) | Ｅｅｄおよびｐｒｃ２調節物質としての大環状アゾロピリジン誘導体 | |
| BR112020003373B1 (pt) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona, usos dos mesmos e composição farmacêutica | |
| JP6434989B2 (ja) | ピリジルピペリジン | |
| TW202404952A (zh) | Qpctl及qpct之抑制劑 | |
| WO2021074279A1 (en) | Spiro-fused tricyclic map4k1 inhibitors | |
| TW202345797A (zh) | 作為ｉｋｚｆ２降解劑之含雙環雜芳基化合物 | |
| WO2021249913A1 (en) | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer | |
| US20240174683A1 (en) | Map4k1 inhibitors | |
| KR20150009599A (ko) | 탄키라아제의 피라노피리돈 억제제 | |
| US10961238B2 (en) | Modulators of hedgehog (Hh) signaling pathway | |
| TW202412784A (zh) | 氮-喹唑啉化合物及使用方法 | |
| CN119384420A (zh) | 新型par-2抑制剂 | |
| HK40123006A (en) | Ikzf2 degraders and uses thereof | |
| HK40123004A (en) | Bicyclic heteroaryl-containing compounds as ikzf2 degraders |